{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:21:45Z","timestamp":1780320105253,"version":"3.54.1"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00393-006-0101-0","type":"journal-article","created":{"date-parts":[[2006,9,26]],"date-time":"2006-09-26T13:57:58Z","timestamp":1159279078000},"page":"505-519","source":"Crossref","is-referenced-by-count":21,"title":["Sj\u00f6gren-Syndrom","Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1007","volume":"65","author":[{"given":"C.","family":"Tomiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"101_CR1","first-page":"371","volume":"142","author":"Ackerman","year":"2006","unstructured":"Ackerman LS (2006) Sex hormones and the genesis of autoimmunity. Arch Dermatol 142(3): 371\u2013376","journal-title":"Arch Dermatol"},{"key":"101_CR2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2165\/00002512-200522110-00001","volume":"22","author":"Al-Hashimi","year":"2005","unstructured":"Al-Hashimi I (2005) Xerostomia secondary to Sj\u00f6gren\u2019s syndrome in the elderly. Drugs Aging 22(11): 887\u2013899","journal-title":"Drugs Aging"},{"key":"101_CR3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/bjo.2005.078865","volume":"90","author":"Aragona","year":"2006","unstructured":"Aragona P, Di Pietro R, Spinella R, Mobrici M (2006) Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren\u2019s syndrome. Br J Ophthalmol 90(2): 166\u2013170","journal-title":"Br J Ophthalmol"},{"key":"101_CR4","unstructured":"Asmussen K, Oxholm P (1999) Disease activity in primary Sj\u00f6gren\u2019s syndrome \u2013 can it be defined and assessed? State of the art lectures on Sj\u00f6gren\u2019s syndrome. Hygiea 108 (part 1) http:\/\/www.sjogrensyndrom.se\/100-site\/index100.html"},{"key":"101_CR5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/rheumatology\/40.10.1085","volume":"40","author":"Asmussen","year":"2001","unstructured":"Asmussen KH, Bowman SJ (2001) Outcome measures in Sj\u00f6gren\u2019s syndrome. Rheumatology 40: 1085\u20131088","journal-title":"Rheumatology"},{"key":"101_CR6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.bor.0000209423.39033.94","volume":"18","author":"Bernatsky","year":"2006","unstructured":"Bernatsky S, Ramsey-Goldman R, Clarke A (2006) Malignancy and autoimmunity. Curr Opin Rheumatol 18(2): 129\u2013134","journal-title":"Curr Opin Rheumatol"},{"key":"101_CR7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00005792-196505000-00001","volume":"44","author":"Bloch","year":"1965","unstructured":"Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ (1965) Sj\u00f6gren\u2019s syndrome, a clinical, pathological and serological study of sixty-two cases. Medicine 44: 187\u2013231","journal-title":"Medicine"},{"key":"101_CR8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/ar599","volume":"4","author":"Bolstad","year":"2002","unstructured":"Bolstad AI, Jonsson R (2002) Genetic aspects of Sj\u00f6gren\u2019s syndrome. Arthritis Res 4: 353\u2013359","journal-title":"Arthritis Res"},{"key":"101_CR9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/rheumatology\/keh170","volume":"43","author":"Bowman","year":"2004","unstructured":"Bowman SJ, Booth DA, Platts RG (2004) Measurement of fatigue and discomfort in primary Sj\u00f6gren\u2019s syndrome using a new questionnaire tool. Rheumatology 43: 758\u2013764","journal-title":"Rheumatology"},{"key":"101_CR10","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/rheumatology\/40.10.1180","volume":"40","author":"Bowman","year":"2001","unstructured":"Bowman SJ, Pillemer S, Jonsson R et al. (2001) Revisiting Sj\u00f6gren\u2019s syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology 40: 1180\u20131188","journal-title":"Rheumatology"},{"key":"101_CR11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/rheumatology\/keh647","volume":"44","author":"Bredberg","year":"2004","unstructured":"Bredberg A, Henriksson G, Larsson \u00c5 et al. (2004) Sj\u00f6gren\u2019s syndrome and the Danger model. Rheumatol 44: 965\u2013970","journal-title":"Rheumatol"},{"key":"101_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2005-857987","volume":"30","author":"Bredberg","year":"2005","unstructured":"Bredberg A, Manthorpe R, Henriksson G (2005) Recent findings shed light on the aethiopathogenesis of Sj\u00f6gren\u2019s syndrome. Akt Rheumatol 30: 1\u20134","journal-title":"Akt Rheumatol"},{"key":"101_CR13","first-page":"1267","volume":"30","author":"Brennan","year":"2003","unstructured":"Brennan MT, Sankar V, Leakan RA et al. (2003) Sex steroid hormones in primary Sjogren\u2019s syndrome. J Rheumatol 30(6): 1267\u20131271","journal-title":"J Rheumatol"},{"key":"101_CR14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.exer.2003.09.019","volume":"78","author":"Bron","year":"2004","unstructured":"Bron AJ, Tiffany JM, Gouveia SM et al. (2004) Functional aspects of the tear film lipid layer. Exp Eye Res 78(3): 347\u2013360","journal-title":"Exp Eye Res"},{"key":"101_CR15","unstructured":"Callaghan R, Prabu A, Allan RB et al. (2006) Direct healthcare costs and predictors of costs in patients with primary Sj\u00f6gren\u2019s syndrome. Rheumatology 25 (Epub ahead of print)"},{"key":"101_CR16","first-page":"296","volume":"33","author":"Cha","year":"2006","unstructured":"Cha S, Singson E, Cornelius J et al. (2006) Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren\u2019s syndrome-associated autoantibodies. J Rheumatol 33(2): 296\u2013306","journal-title":"J Rheumatol"},{"key":"101_CR17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/art.21990","volume":"55","author":"Champey","year":"2006","unstructured":"Champey J, Corruble E, Gottenberg JE et al. (2006) Quality of life and psychological status in patients with primary Sjogren\u2019s syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 55(3): 451\u2013457","journal-title":"Arthritis Rheum"},{"key":"101_CR18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jcp.21.5.656","volume":"21","author":"Chisholm","year":"1968","unstructured":"Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sj\u00f6gren\u2019s disease. J Clin Pathol 21: 656\u2013660","journal-title":"J Clin Pathol"},{"key":"101_CR19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00431-003-1277-9","volume":"162","author":"Cimaz","year":"2003","unstructured":"Cimaz R, Casadei A, Rose C et al. (2003) Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr 162(10): 661\u2013665","journal-title":"Eur J Pediatr"},{"key":"101_CR20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","volume":"49","author":"Cummins","year":"2003","unstructured":"Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sj\u00f6gren\u2019s syndrome with low-dose human interferon-\u03b1 administered by the oromucosal route: combined phase III results. Arthritis Rheum 49:585\u2013593","journal-title":"Arthritis Rheum"},{"key":"101_CR21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1191\/0961203304lu1094oa","volume":"13","author":"Cutolo","year":"2004","unstructured":"Cutolo M, Sulli A, Capellino S et al. (2004) Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13(9): 635\u2013638","journal-title":"Lupus"},{"key":"101_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/ard.46.2.89","volume":"46","author":"Dalavanga","year":"1987","unstructured":"Dalavanga YA, Detrick B, Hooks JJ et al. (1987) Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjogren\u2019s syndrome. Ann Rheum Dis 46(2): 89\u201392","journal-title":"Ann Rheum Dis"},{"key":"101_CR23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1350-9462(02)00038-1","volume":"21","author":"Dartt","year":"2002","unstructured":"Dartt DA (2002) Regulation of mucin and fluid secretion by conjunctival epithelial cells. Progress Retinal Eye Res 21: 555\u2013576","journal-title":"Progress Retinal Eye Res"},{"key":"101_CR24","doi-asserted-by":"crossref","unstructured":"Davidson BK, Kelly CA, Griffiths ID (1999) Primary Sjogren\u2019s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) 38(3): 245\u2013253","DOI":"10.1093\/rheumatology\/38.3.245"},{"key":"101_CR25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.21764","volume":"54","author":"Dawson","year":"2006","unstructured":"Dawson LJ, Stanbury J, Venn N et al. (2006) Antimuscarinic antibodies in primary Sjogren\u2019s syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 54(4): 1165\u20131173","journal-title":"Arthritis Rheum"},{"key":"101_CR26","unstructured":"Diener HC, Putzki N, Berlit P et al. (2005) Diagnostik und Therapie der vaskulitischen Neuropathien und Neuropathien bei Kollagenosen; Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie, 3. \u00fcberarbeitete Aufl. Georg Thieme, Stuttgart, http:\/\/www.uni-duesseldorf.de\/awmf\/ll\/030\u2013068.htm"},{"key":"101_CR27","unstructured":"D\u00f6rner T (2001) Neonatale Lupussyndrome. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplin\u00e4re klinische Rheumatologie. Springer, Berlin Heidelberg New York Tokyo, S 865\u2013894"},{"key":"101_CR28","unstructured":"D\u00f6rner T (2001) Sj\u00f6gren Syndrom. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplin\u00e4re klinische Rheumatologie. Springer, Berlin Heidelberg New York Tokyo, S 922\u2013928"},{"key":"101_CR29","unstructured":"D\u00f6rner T, Gromnica-Ihle E (2006) Sj\u00f6gren-Syndrom, Kapitel 4.1. In: Rationelle Diagnostik und Therapie in der Inneren Medizin. Elsevier\/Urban Fischer, M\u00fcnchen Jena"},{"key":"101_CR30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/ar603","volume":"4","author":"D\u00f6rner","year":"2002","unstructured":"D\u00f6rner T, Lipsky PE (2002) Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sj\u00f6gren\u2019s syndrome. Arthritis Res 4: 360\u2013371","journal-title":"Arthritis Res"},{"key":"101_CR31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/rheumatology\/27.2.123","volume":"27","author":"Drosos","year":"1988","unstructured":"Drosos AA, Andonopoulos AP, Costopoulos JS et al. (1988) Prevalence of primary Sj\u00f6gren\u2019s syndrome in an elderly population. Rheumatology 27: 123\u2013127","journal-title":"Rheumatology"},{"key":"101_CR32","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","volume":"45","author":"Drosos","year":"1986","unstructured":"Drosos AA, Skopouli FN, Costopoulos JS et al. (1986) Cyclosporin A (CyA) in primary Sjogren\u2019s syndrome: a double blind study. Ann Rheum Dis 45(9): 732\u2013735","journal-title":"Ann Rheum Dis"},{"key":"101_CR33","first-page":"246","volume":"61","author":"Drosos","year":"1986","unstructured":"Drosos AA, Skopouli FN, Galanopoulou VK et al. (1986) Cyclosporin a therapy in patients with primary Sjogren\u2019s syndrome: results at one year. Scand J Rheumatol Suppl 61: 246\u2013249","journal-title":"Scand J Rheumatol Suppl"},{"key":"101_CR34","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","volume":"162","author":"Fife","year":"2002","unstructured":"Fife RS, Chase WF, Dore RK et al. (2002) Cevimeline for the treatment of xerostomia in patients with Sj\u00f6gren syndrome: a randomized trial. Arch Internal Med 162: 1293\u20131300","journal-title":"Arch Internal Med"},{"key":"101_CR35","first-page":"149","volume":"11","author":"Fox","year":"1993","unstructured":"Fox PC, Datiles M, Atkinson JC et al. (1993) Prednisone and Piroxicam for treatment of primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 11: 149\u2013156","journal-title":"Clin Exp Rheumatol"},{"key":"101_CR36","doi-asserted-by":"crossref","unstructured":"Fox RI, Chan E, Benton L (1986) Treatment of primary Sj\u00f6gren\u2019s syndrome with hydroxychloroquine. Am J Med 85 [Suppl 4A]: 62\u201370","DOI":"10.1016\/0002-9343(88)90365-8"},{"key":"101_CR37","unstructured":"Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sj\u00f6gren\u2019s syndrome with hydroxychloroquin: a retrospective, open-label study. Lupus 5 [Suppl 1]: S31\u2013S36"},{"key":"101_CR38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1749-6632.2002.tb04232.x","volume":"966","author":"Godaert","year":"2002","unstructured":"Godaert GLR, Hartkamp A, Geenen R et al. (2002) Fatigue in daily life in patients with primary Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus. Ann NY Acad Sci 966: 320\u2013326","journal-title":"Ann NY Acad Sci"},{"key":"101_CR39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1529-0131(200007)43:7<1647::AID-ANR31>3.0.CO;2-P","volume":"43","author":"Waterman","year":"2000","unstructured":"Waterman SA, Gordon TP, Rischmueller M (2000) Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren\u2019s syndrome. Arthritis Rheum 43(7): 1647\u20131654","journal-title":"Arthritis Rheum"},{"key":"101_CR40","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"Gottenberg","year":"2005","unstructured":"Gottenberg JE, Guillevin L, Lambotte O et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64(6): 913\u2013920","journal-title":"Ann Rheum Dis"},{"key":"101_CR41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","volume":"109","author":"Groom","year":"2002","unstructured":"Groom J, Kalled SL, Cutler AH et al. (2002) Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren\u2019s syndrome. J Clin Invest 109(1): 59\u201368","journal-title":"J Clin Invest"},{"key":"101_CR42","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/rheumatology\/32.12.1072","volume":"32","author":"Gudbj","year":"1993","unstructured":"Gudbj\u00f6rnsson B, Broman JE, Hetta J, H\u00e4llgren R (1993) Sleep disturbances in patients with primary Sj\u00f6gren\u2019s syndrome. Rheumatology 32: 1072\u20131076","journal-title":"Rheumatology"},{"key":"101_CR43","unstructured":"Hamilton JB (1943) A new conception of Keratoconjunctivitis sicca (keratitis filiformis in hypofunction of the lacrimal glands). Australasian Medical Publishing Company, Sydney"},{"key":"101_CR44","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.20276","volume":"50","author":"Hansen","year":"2004","unstructured":"Hansen A, Gosemann M, Pruss A et al. (2004) Abnormalities in peripheral B cell memory of patients with primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 50: 1897\u20131908","journal-title":"Arthritis Rheum"},{"key":"101_CR45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-2005-857934","volume":"30","author":"Hansen","year":"2005","unstructured":"Hansen A, Hoffmann A, D\u00f6rner T (2005) Sj\u00f6gren-Syndrom \u2013 k\u00f6nnen wir das Lymphomrisiko stratifizieren? Akt Rheumatol 30: 46\u201349","journal-title":"Akt Rheumatol"},{"key":"101_CR46","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.bor.0000172801.56744.c3","volume":"17","author":"Hansen","year":"2005","unstructured":"Hansen A, Lipsky PE, Dorner T (2005) Immunopathogenesis of primary Sjogren\u2019s syndrome: implications for disease management and therapy. Curr Opin Rheumatol 17(5): 558\u2013565","journal-title":"Curr Opin Rheumatol"},{"key":"101_CR47","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/art.10445","volume":"46","author":"Hansen","year":"2002","unstructured":"Hansen A, Odendahl M, Reiter K et al. (2002) Disturbed B cell homeostasis in Sj\u00f6gren\u2019s syndrome: indication for the accumulation of memory B cells in the salivary glands. Arthritis Rheum 46: 2160\u20132171","journal-title":"Arthritis Rheum"},{"key":"101_CR48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/art.21558","volume":"54","author":"Hansen","year":"2006","unstructured":"Hansen A, Reiter K, Pruss A et al. (2006) Dissemination of a Sj\u00f6gren\u2018s syndrome-associated extranodal marginal zone B cell lymphoma. Arthritis Rheum 54: 127\u2013137","journal-title":"Arthritis Rheum"},{"key":"101_CR49","first-page":"1","volume":"1","author":"H\u00f6ld","year":"1995","unstructured":"H\u00f6ld KM, de Boer D, Zuidema J, Maes RAA (1995) Saliva as an analytical tool in toxicology. Int J Drug Testing 1(1): 1\u201336 (http:\/\/www.criminology.fsu.edu\/journal\/hold.pdf)","journal-title":"Int J Drug Testing"},{"key":"101_CR50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","volume":"46","author":"Ioannidis","year":"2002","unstructured":"Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 46(3): 741\u2013747","journal-title":"Arthritis Rheum"},{"key":"101_CR51","first-page":"24","volume":"77","author":"Isenberg","year":"2006","unstructured":"Isenberg DA (2006) B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 77: 24\u201328","journal-title":"J Rheumatol Suppl"},{"key":"101_CR52","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar1912","volume":"8","author":"Ittah","year":"2006","unstructured":"Ittah M, Miceli-Richard C, Eric Gottenberg J et al. (2006) B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sj\u00f6gren\u2019s syndrome. Arthritis Res Therapy 8: R51","journal-title":"Arthritis Res Therapy"},{"key":"101_CR53","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","volume":"89","author":"Kassan","year":"1978","unstructured":"Kassan SS, Thomas TL, Moutsopoulos HM et al. (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6): 888\u2013892","journal-title":"Ann Intern Med"},{"key":"101_CR54","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/rheumatology\/keg290","volume":"42","author":"Kassi","year":"2003","unstructured":"Kassi E, Moutsatsou P, Sekeris CE et al. (2003) Oestrogen receptors in cultured epithelial cells from salivary glands of Sj\u00f6gren\u2019s syndrome patients. Rheumatology 42: 1120\u20131122","journal-title":"Rheumatology"},{"key":"101_CR55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1018472213872","volume":"8","author":"Kauppi","year":"1997","unstructured":"Kauppi M, Pukkala L, Isom\u00e4ki H (1997) Elevated incidence of hematologic malignancies in patients with Sj\u00f6gren\u2019s syndrome compared with patients, with rheumatoid arthritis (Finland). Cancer Causes Control 8: 201\u2013214","journal-title":"Cancer Causes Control"},{"key":"101_CR56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","volume":"52","author":"Kruize","year":"1993","unstructured":"Kruize AA, H\u00e9ne RJ, Kallenberg CGM et al. (1993) Hydroxychloroquine treatment for primary Sj\u00f6gren\u2019s syndrome: a two-year, double-blind cross-over trial. Ann Rheum Dis 52: 360\u2013364","journal-title":"Ann Rheum Dis"},{"key":"101_CR57","doi-asserted-by":"crossref","unstructured":"Lazarus MN, Robinson D, Mak V et al. (2006) Incidence of cancer in a cohort of patients with primary Sj\u00f6gren\u2019s syndrome. Rheumatology, Advance Access published on February 20, 2006. doi: 10.1093\/rheumatology\/kei281","DOI":"10.1093\/rheumatology\/kei281"},{"key":"101_CR58","first-page":"159","volume":"20","author":"Leng","year":"2005","unstructured":"Leng XM, Zhao Y, Zhou DB et al. (2005) A pilot trial for severe, refractory systemic autoimmune disease with stem cell transplantation. Chin Med Sci J 20(3): 159\u2013165 (abstract)","journal-title":"Chin Med Sci J"},{"key":"101_CR59","unstructured":"Lipsky PE, Diamond B (2006) Autoimmunity and autoimmune diseases, Chapter 8. In: Fauci AS (ed) Harrison\u2019s rheumatology. McGraw-Hill Medical Publishing Division, New York, p 63"},{"key":"101_CR60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-2005-857949","volume":"30","author":"Manthorpe","year":"2005","unstructured":"Manthorpe R (2005) Wie klassifizieren wir Patienten, bei den wir ein Sj\u00f6gren-Syndrom vermuten? Geschichtliche Entwicklung verschiedener Klassifikationen und vermutliche Weiterentwicklung. Akt Rheumatol 30: 32\u201337","journal-title":"Akt Rheumatol"},{"key":"101_CR61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ard.59.1.54","volume":"59","author":"Manthorpe","year":"2000","unstructured":"Manthorpe R, Benoni C, Jacobsson L et al. (2000) Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA\/Ro and anti-SSB\/La antibodies in Sjogren\u2019s syndrome? Ann Rheum Dis 59(1): 54\u201360","journal-title":"Ann Rheum Dis"},{"key":"101_CR62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2005-857986","volume":"30","author":"Manthorpe","year":"2005","unstructured":"Manthorpe R, Manthorpe T (2005) Das prim\u00e4re Sj\u00f6gren-Syndrom \u2013 Epidemiologie und Prognose. Akt Rheumatol 30: 27\u201331","journal-title":"Akt Rheumatol"},{"key":"101_CR63","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"Mariette","year":"2004","unstructured":"Mariette X, Ravaud P, Steinfeld S et al. (2004) Inefficacy of infliximab in primary Sjogren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren\u2019s Syndrome (TRIPSS). Arthritis Rheum 50(4): 1270\u20131276","journal-title":"Arthritis Rheum"},{"key":"101_CR64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1568-9972(03)00102-2","volume":"3","author":"Masaki","year":"2004","unstructured":"Masaki Y, Sugai S (2004) Lymphoproliferative disorders in Sjogren\u2019s syndrome. Autoimmun Rev 3(3): 175\u2013182","journal-title":"Autoimmun Rev"},{"key":"101_CR65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2005-857939","volume":"30","author":"Messmer","year":"2005","unstructured":"Messmer EM (2005) Differenzierte Therapie der Keratoconjunctivitis sicca beim Sj\u00f6gren-Syndrom. Akt Rheumatol 30: 59\u201365","journal-title":"Akt Rheumatol"},{"key":"101_CR66","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2249.2002.01869.x","volume":"128","author":"Mitsias","year":"2002","unstructured":"Mitsias DI, Tzioufas G, Veiopoulou C et al. (2002) The Th1\/Th2 cytokine balance changes with the progress of the immunological lesion of Sjogren\u2019s syndrome. Clin Exp Immunol 128: 562\u2013568","journal-title":"Clin Exp Immunol"},{"key":"101_CR67","unstructured":"Moutsopoulos HM (2006) Sj\u00f6gren\u2019s syndrom, Chapter 8. In: Fauci AS (ed) Harrison\u2019s rheumatology. McGraw-Hill Medical Publishing Division, New York, pp 133\u2013138"},{"key":"101_CR68","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.4049\/jimmunol.176.7.3950","volume":"176","author":"Niederkorn","year":"2006","unstructured":"Niederkorn JY, Stern ME, Pflugfelder SC et al. (2006) Desiccating stress induces T cell-mediated Sjogren\u2019s Syndrome-like lacrimal keratoconjunctivitis. J Immunol 176(7): 3950\u20133957","journal-title":"J Immunol"},{"key":"101_CR69","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","volume":"88","author":"Noble","year":"2004","unstructured":"Noble BA, Loh RSK, MacLennan S et al. (2004) Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Opthalmol 88: 647\u2013652","journal-title":"Br J Opthalmol"},{"key":"101_CR70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","volume":"138","author":"Ono","year":"2004","unstructured":"Ono M, Takamura E, Shinozaki K et al. (2004) Therapeutic effect of cevimeline on dry eye in patients with Sjogren\u2019s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 138(1): 6\u201317","journal-title":"Am J Ophthalmol"},{"key":"101_CR71","unstructured":"Palombi G, the Study Group for SjS of the Italian Society of Rheumatology (2006) Sj\u00f6gren\u2019s syndrome Disease Damage Index (SjSDDI) a scoring system for the quantification of damage in SjS, derived by the analysis of a cohort of Italian patients. Posterpr\u00e4sentation IX. International Symposium on Sjogren\u2019s Syndrom Washighton DC 27.\u201329.4.2006"},{"key":"101_CR72","first-page":"180","volume":"1","author":"Paulsen","year":"2003","unstructured":"Paulsen FP, Schaudig U, Thale AB (2003) Drainage of tears: impact on the ocular surface and lacrimal system. Clin Sci 1(4): 180\u2013191","journal-title":"Clin Sci"},{"key":"101_CR73","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/ard.2005.040956","volume":"65","author":"Pertovaara","year":"2006","unstructured":"Pertovaara M, Antonen J, Hurme M (2006) Th2 cytokine genotypes are associated with a milder form of primary Sjogren\u2019s syndrome. Ann Rheum Dis 65(5): 666\u2013670","journal-title":"Ann Rheum Dis"},{"key":"101_CR74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/ard.60.5.467","volume":"60","author":"Pertovaara","year":"2001","unstructured":"Pertovaara M, Pukkala E, Laippala P et al. (2001) A longitudinal cohort study of Finnish patients with primary Sj\u00f6gren\u2019s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60: 467\u2013472","journal-title":"Ann Rheum Dis"},{"key":"101_CR75","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"Pijpe","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FK et al. (2005) Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study. Arthritis Rheum 52(9): 2740\u20132750","journal-title":"Arthritis Rheum"},{"key":"101_CR76","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20540","volume":"51","author":"Pillemer","year":"2004","unstructured":"Pillemer SR, Brennan MT, Sankar V et al. (2004) Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren\u2019s syndrome. Arthritis Rheum 51(4): 601\u2013604","journal-title":"Arthritis Rheum"},{"key":"101_CR77","unstructured":"Pleyer U, D\u00f6rner T (2001) Sj\u00f6gren Syndrom \u2013 systemische und ophthalmologische Manifestationen. Uni-Med Taschenbuch Augenheilkunde, 1. Aufl. Uni-Med, Bremen, S 80\u201389, 103\u2013104"},{"key":"101_CR78","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1755-3768.1984.tb08430.x","volume":"62","author":"Prause","year":"1984","unstructured":"Prause JU, Frost-Larsen K, Hoj L et al. (1984) Lacrimal and salivary secretion in Sjogren\u2019s syndrome: the effect of systemic treatment with bromhexine. Acta Ophthalmol (Copenh) 62(3): 489\u2013497","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"101_CR79","first-page":"896","volume":"25","author":"Price","year":"1998","unstructured":"Price EJ, Rigby SP, Clancy U, Venables PJ (1998) Double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren\u2019s syndrome. J Rheumatol 25(5): 896\u2013899","journal-title":"J Rheumatol"},{"key":"101_CR80","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keh714","volume":"44","author":"Ramos-Casals","year":"2005","unstructured":"Ramos-Casals M, Font J (2005) Primary Sj\u00f6gren\u2019s syndrome: current and emergent aetiopathogenic concepts. Rheumatology 44: 1354\u20131367","journal-title":"Rheumatology"},{"key":"101_CR81","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.semarthrit.2005.12.004","volume":"35","author":"Ramos-Casals","year":"2006","unstructured":"Ramos-Casals M, Nardi N, Brito-Zeron P et al. (2006) Atypical autoantibodies in patients with primary Sjogren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35(5): 312\u2013321","journal-title":"Semin Arthritis Rheum"},{"key":"101_CR82","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1600-0668.2003.00155.x","volume":"13","author":"Reinikainen","year":"2003","unstructured":"Reinikainen LM, Jaakkola JJ (2003) Significance of humidity and temperature on skin and upper airway symptoms. Indoor Air 13(4): 344\u2013352","journal-title":"Indoor Air"},{"key":"101_CR83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0896-1549(02)00067-6","volume":"16","author":"Rosenthal","year":"2003","unstructured":"Rosenthal P, Cotter J (2003) The Boston Scleral Lens in the management of severe ocular surface disease. Ophthalmol Clin North Am 16(1): 89\u201393","journal-title":"Ophthalmol Clin North Am"},{"key":"101_CR84","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.11311","volume":"48","author":"Salomonsson","year":"2003","unstructured":"Salomonsson S, Jonsson MV, Skarstein K et al. (2003) Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren\u2019s syndorm. Arthritis Rheum 48(11): 3187\u20133201","journal-title":"Arthritis Rheum"},{"key":"101_CR85","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/keh455","volume":"44","author":"S\u00e1nchez-Guerrero","year":"2005","unstructured":"S\u00e1nchez-Guerrero J, P\u00e9rez-Dosal MR, C\u00e1rdenas-Vel\u00e1zquez F et al. (2005) Prevalence of Sj\u00f6gren\u2019s syndrome in ambulatory patients according to the American-European Consensus Group criteria. Rheumatology 44: 235\u2013240","journal-title":"Rheumatology"},{"key":"101_CR86","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"Sankar","year":"2004","unstructured":"Sankar V, Brennan MT, Kok MR et al. (2004) Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50: 2240\u20132245","journal-title":"Arthritis Rheum"},{"key":"101_CR87","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1172\/JCI3234","volume":"102","author":"Scott","year":"1998","unstructured":"Scott D, Hiepe F, Hummel M et al. (1998) Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren\u2019s syndrome. J Clin Invest 102(5): 938\u2013946","journal-title":"J Clin Invest"},{"key":"101_CR88","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/bmj.325.7362.480","volume":"325","author":"Sharpe","year":"2002","unstructured":"Sharpe M, Wilks D (2002) ABC of psychological medicine: Fatigue. BMJ 325: 480\u2013483","journal-title":"BMJ"},{"key":"101_CR89","unstructured":"Sj\u00f6gren HSC (1933) Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tr\u00e4nendr\u00fcsen). Acta Ophthalmologica, Copenhagen [Suppl\u00a0II]: 1\u2013151"},{"key":"101_CR90","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","volume":"29","author":"Skopouli","year":"2000","unstructured":"Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of primary Sjogren\u2019s syndrome. Semin Arthritis Rheum 29(5): 296\u2013304","journal-title":"Semin Arthritis Rheum"},{"key":"101_CR91","first-page":"555","volume":"14","author":"Skopouli","year":"1996","unstructured":"Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM (1996) Methotrexate in primary Sjogren\u2019s syndrome. Clin Exp Rheumatol 14(5): 555\u2013558","journal-title":"Clin Exp Rheumatol"},{"key":"101_CR92","unstructured":"Stangel M, Gold Rolf f\u00fcr die IVIg-Konsensusgruppe: Einsatz intraven\u00f6ser Immunglobuline in der Neurologie \u2013 ein evidenzbasierter Konsens, S.\u00a029. http:\/\/www.dgn.org\/fileadmin\/leitl\/ivigkonsensgruppe.pdf"},{"key":"101_CR93","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","volume":"46","author":"Steinfeld","year":"2002","unstructured":"Steinfeld SD, Demols P, Appelboom T (2002) Infliximab in primary Sjogren\u2019s syndrome: one-year followup. Arthritis Rheum 46(12): 3301\u20133303","journal-title":"Arthritis Rheum"},{"key":"101_CR94","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","volume":"44","author":"Steinfeld","year":"2001","unstructured":"Steinfeld SD, Demols P, Salmon I et al. (2001) Infliximab in patients with primary Sjogren\u2019s syndrome: a pilot study. Arthritis Rheum 44(10): 2371\u20132375","journal-title":"Arthritis Rheum"},{"key":"101_CR95","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"Steinfeld","year":"2006","unstructured":"Steinfeld SD, Tant L, Burmester GR et al. (2006) Epratzumab (humanized anti-CD22 antibody) in primary Sjogren\u2019s syndrome: an open-label Phase I\/II study. Arthritis Res Ther 8: R129 (http:\/\/arthritis-research.com\/content\/pdf\/ar2018.pdf)","journal-title":"Arthritis Res Ther"},{"key":"101_CR96","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","volume":"17","author":"Stern","year":"1998","unstructured":"Stern ME, Beuerman RW, Fox RI et al. (1998) The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17(6): 584\u2013589","journal-title":"Cornea"},{"key":"101_CR97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2005-857933","volume":"30","author":"Stiller","year":"2005","unstructured":"Stiller M (2005) Die orale Komponente des Sj\u00f6gren-Syndroms \u2013 diagnostische Aspekte und zahnmedizinisch-therapeutische Konsequenzen. Akt Rheumatol 30: 41\u201345","journal-title":"Akt Rheumatol"},{"key":"101_CR98","first-page":"1326","volume":"29","author":"Stroehmann","year":"2002","unstructured":"Stroehmann A, D\u00f6rner T, Lukowsky A et al. (2002) Cutaneous T cell lymphoma in a patient with primary biliary cirrhosis and secondary Sj\u00f6gren\u2019s syndrome. J Rheumatol 29: 1326\u20131330","journal-title":"J Rheumatol"},{"key":"101_CR99","unstructured":"Str\u00f6mbeck B (2006) Women with primary Sj\u00f6gren\u2019s syndrome; assessment and treatment; a physiotherapeutic perspective. Doctoral Thesis, Lund University"},{"key":"101_CR100","first-page":"3732","volume":"41","author":"Sullivan","year":"2000","unstructured":"Sullivan DA, Sullivan BD, Ullman MD et al. (2000) Androgen influence on the Meibomian gland. Invest Ophthalmol Vis Sci 41: 3732\u20133742","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"101_CR101","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0049-0172(98)80040-1","volume":"28","author":"Sutcliffe","year":"1998","unstructured":"Sutcliffe NN, Inanc M, Speight P, Isenberg D (1998) Predictors of lymphoma development in primary Sj\u00f6gren\u2019s syndrome. Semin Arthritis Rheum 28: 80\u201387","journal-title":"Semin Arthritis Rheum"},{"key":"101_CR102","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-3083.2005.01688.x","volume":"62","author":"Szodoray","year":"2005","unstructured":"Szodoray P, Jonsson R (2005) The BAFF\/APRIL system in systemic autoimmune diseases with a special emphasis on Sj\u00f6gren\u2019s syndrome. Scand J Immunol 62(5): 421\u2013428","journal-title":"Scand J Immunol"},{"key":"101_CR103","first-page":"358","volume":"15","author":"Tabbara","year":"1993","unstructured":"Tabbara KF, Frayha RA (1993) Alternate-day steroid therapy for patients with primary Sj\u00f6gren\u2019s syndrome. Ann Ophthal 15: 358\u2013361","journal-title":"Ann Ophthal"},{"key":"101_CR104","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0002-9343(64)90101-9","volume":"36","author":"Talal","year":"1964","unstructured":"Talal N, Bunim JJ (1964) The development of malignant lymphoma in the course of Sj\u00f6gren\u2019s syndrome. Am J Med 36: 529\u2013540","journal-title":"Am J Med"},{"key":"101_CR105","unstructured":"Theander E (2005) Living and dying with primary Sj\u00f6gren\u2019s syndrome. Studies on aetiology, treatment, lymphoma, survival and predictors. Thesis. Lund University, Malm\u00f6, pp 1\u2013144"},{"key":"101_CR106","first-page":"1495","volume":"32","author":"Theander","year":"2005","unstructured":"Theander E, Andersson SI, Manthorpe R, Jocobsson LTH (2005) Proposed core set of outcome measures in patients with primary Sj\u00f6gren\u2019s syndrome. A 5 years follow-up. J Rheumatol 32: 1495\u20131502","journal-title":"J Rheumatol"},{"key":"101_CR107","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","volume":"65","author":"Theander","year":"2006","unstructured":"Theander E, Henriksson G, Ljungberg O et al. (2006) Lymphoma and other malignancies in primary Sjogren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65(6): 796\u2013803","journal-title":"Ann Rheum Dis"},{"key":"101_CR108","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.20176","volume":"50","author":"Theander","year":"2004","unstructured":"Theander E, Manthorpe R, Jacobsson LT (2004) Mortality and causes of death in primary Sjogren\u2019s syndrome: a prospective cohort study. Arthritis Rheum 50(4): 1262\u20131269","journal-title":"Arthritis Rheum"},{"key":"101_CR109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.58.4.253","volume":"58","author":"Tishler","year":"1999","unstructured":"Tishler M, Yaron I, Shirazi I, Yaron M (1999) Hydroxychloroquine treatment for primary Sjogren\u2019s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58: 253\u2013256","journal-title":"Ann Rheum Dis"},{"key":"101_CR110","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","volume":"62","author":"Tsifetaki","year":"2003","unstructured":"Tsifetaki N, Kitsos G, Paschides CA et al. (2003) Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren\u2019s syndrome: a randomised 12 week controlled study. Ann Rheum Dis 62(12): 1204\u20131207","journal-title":"Ann Rheum Dis"},{"key":"101_CR111","first-page":"2376","volume":"24","author":"Valesini","year":"1997","unstructured":"Valesini G, Priori R, Bavoillot D et al. (1997) Differential risk of non-Hodgkin\u2019s lymphoma in Italian patients with primary Sjogren\u2019s syndrome. J Rheumatol 24(12): 2376\u20132380","journal-title":"J Rheumatol"},{"key":"101_CR112","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1677\/joe.0.1800055","volume":"180","author":"Valimaa","year":"2004","unstructured":"Valimaa H, Savolainen S, Soukka T et al. (2004) Estrogen receptor-beta is the predominant subtype in human oral epithelium and salivary glands. J Endocrinol 180(1): 55\u201362","journal-title":"J Endocrinol"},{"key":"101_CR113","first-page":"597","volume":"18","author":"Valti\u00fdsd\u00f3ttir","year":"2000","unstructured":"Valti\u00fdsd\u00f3ttir ST, Gudjbj\u00f6rnsson B, H\u00e4llgren R, Hetta J (2000) Psychological well-being in patients with primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 18: 597\u2013600","journal-title":"Clin Exp Rheumatol"},{"key":"101_CR114","unstructured":"van Woerkom J, Kruize AA, Jacobs KMG et al. (2006) Clinical efficacy of leflunomide in the treatment of primary Sj\u00f6gren\u2019s syndrome correlates with a decrease in pro-inflammatory cytokine production. SAT0105 EULAR 2006"},{"key":"101_CR115","unstructured":"van Woerkom J, Kruize AA, Jacobs KMG et al. (2005) Safety and efficacy of leflunomide in primary Sj\u00f6gren\u2019s syndrome: preliminary results of a pilot study. FRI0172 EULAR 2005"},{"key":"101_CR116","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R et al. (2002) Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the America-European-Consensus Group. Ann Rheum Dis 61: 554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"101_CR117","unstructured":"Vitali C, Palombi G, the Study Group for SjS of the Italian Society of Rheumatology (2006) Sj\u00f6gren\u2019s syndrome Disease Activity Measurement (SjSDAM): a scoring system fort he assessment of disease acitivty in SjS, derived by the analysis of a cohort of Italian patients. Posterpr\u00e4sentation IX. International Symposium on Sjogren\u2019s Syndrom Washighton DC 27.\u201329.4.2006"},{"key":"101_CR118","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","volume":"159","author":"Vivino","year":"1999","unstructured":"Vivino FB, Al-Hashimi I, Khan Z et al. (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Internal Med 159: 174\u2013181","journal-title":"Arch Internal Med"},{"key":"101_CR119","doi-asserted-by":"crossref","unstructured":"Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM (2005) Long-term remission of Sjogren\u2019s syndrome-associated aggressive B-cell non-Hodgkin\u2019s lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis published Online First: 1 December 2005. doi: 10.1136\/ard.2005.046193","DOI":"10.1136\/ard.2005.046193"},{"key":"101_CR120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00002281-199002050-00002","volume":"2","author":"Youinou","year":"1990","unstructured":"Youinou P, Moutsopoulos HM, Pennec YL (1990) Clinical features of Sjogren\u2019s syndrome. Curr Opin Rheumatol 2(5): 687\u2013693","journal-title":"Curr Opin Rheumatol"},{"key":"101_CR121","unstructured":"Zandbelt MM, Blokx WA, DeJong EM et al. (2006) Expression of estrogen receptors alpha and beta in skin and salivary gland biospy specimens of Sj\u00f6gren\u2019s syndrome patients. Posterpr\u00e4sentation EULAR-Kongress Amsterdam SAT 0110"},{"key":"101_CR122","first-page":"96","volume":"31","author":"Zandbelt","year":"2004","unstructured":"Zandbelt MM, de Wilde P, van Damme P et al. (2004) Etanercept in the treatment of patients with primary Sjogren\u2019s syndrome: a pilot study. J Rheumatol 31(1): 96\u2013101","journal-title":"J Rheumatol"},{"key":"101_CR123","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","volume":"165","author":"Zintzaras","year":"2005","unstructured":"Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20): 2337\u20132344","journal-title":"Arch Intern Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-006-0101-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-006-0101-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-006-0101-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:29:37Z","timestamp":1559060977000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-006-0101-0"}},"subtitle":["Aktuelle Aspekte aus rheumatologischer Sicht","Current aspects from a rheumatological point of view"],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1007\/s00393-006-0101-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}